scholarly journals Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?

2007 ◽  
Vol 20 (8) ◽  
pp. 856-863 ◽  
Author(s):  
Guo-Xia Tong ◽  
Luis Chiriboga ◽  
Diane Hamele-Bena ◽  
Alain C Borczuk
Keyword(s):  
Fallopian Tube ◽  
Serous Carcinoma ◽  
Immunohistochemical Evidence ◽  
Papillary Serous Carcinoma ◽  
Carcinoma Of The Ovary

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube

2012 ◽  
Vol 125 (3) ◽  
pp. 640-645 ◽  
Author(s):  
Ignacio Romero Noguera ◽  
Charlotte C. Sun ◽  
Russell R. Broaddus ◽  
Donna Branham ◽  
Charles F. Levenback ◽  
...  
Keyword(s):  
Imatinib Mesylate ◽  
Fallopian Tube ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Carcinoma Of The Ovary

Papillary Serous Carcinoma of the Ovary: An Ultrastructural and Immunohistochemical Study

2004 ◽  
Vol 28 (3) ◽  
pp. 141-147 ◽  
Author(s):  
Zhenhe Suo ◽  
Kleonora Karbove ◽  
Claes Trope ◽  
Krassimir Metodiev ◽  
Jahn Nesland
Keyword(s):  
Immunohistochemical Study ◽  
Serous Carcinoma ◽  
Papillary Serous Carcinoma ◽  
Carcinoma Of The Ovary

scholarly journals Trisomy 8 in papillary serous carcinoma of the ovary studied by FISH

1999 ◽  
Vol 1 (2) ◽  
pp. 66-66
Author(s):  
A Afify ◽  
M Samy ◽  
C-L Sun ◽  
H F L Mark
Keyword(s):  
Serous Carcinoma ◽  
Trisomy 8 ◽  
Papillary Serous Carcinoma ◽  
Carcinoma Of The Ovary

Abstract 1714: Chemoresistance in patients with papillary serous carcinoma of the ovary

2011 ◽  
Author(s):  
Elizabeth H. Kerr ◽  
Peter J. Frederick ◽  
Denise K. Oelschlager ◽  
Hope Amm ◽  
Jeffery Sellers ◽  
...  
Keyword(s):  
Serous Carcinoma ◽  
Papillary Serous Carcinoma ◽  
Carcinoma Of The Ovary

Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary

2008 ◽  
Vol 18 (2) ◽  
pp. 379-383 ◽  
Author(s):  
A. Jaishuen ◽  
J. P. Berrios-Rivera ◽  
N. Sirisabya ◽  
H. G. Zheng ◽  
Y. Li ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Wound Healing ◽  
Recurrent Ovarian Cancer ◽  
Serous Carcinoma ◽  
Delayed Wound Healing ◽  
Erosive Osteoarthritis ◽  
First Case ◽  
Papillary Serous Carcinoma ◽  
Carcinoma Of The Ovary ◽  
Symptoms And Signs

Bevacizumab (BVC) is currently used in recurrent ovarian cancer and as part of the initial treatment for ovarian cancer. The most serious toxicities associated with BVC include gastrointestinal perforations, delayed wound healing, and hemorrhage. Arthritis had never been addressed in patients who received BVC treatment. This is the first case report of arthritis emergence linked to BVC administration. A 59-year-old female with recurrent ovarian cancer received multiple hormonal and cytotoxic regimens for 5 years and then developed erosive osteoarthritis of the hands secondary to BVC and paclitaxel. This effect was confirmed by a significant improvement in her symptoms and signs, after treatment was discontinued.

scholarly journals Can morphometric analysis of the fallopian tube fimbria predict the presence of uterine papillary serous carcinoma (UPSC)?

PLoS ONE ◽  
2019 ◽  
Vol 14 (2) ◽  
pp. e0211329
Author(s):  
Amnon Amit ◽  
Edmond Sabo ◽  
Avielle Movsas ◽  
Yamit Efrat–Tamam ◽  
Ari Reiss ◽  
...  
Keyword(s):  
Fallopian Tube ◽  
Morphometric Analysis ◽  
Serous Carcinoma ◽  
Uterine Papillary Serous Carcinoma ◽  
Papillary Serous Carcinoma
Sign in / Sign up

Export Citation Format

Share Document